Cipla Ltd. has announced the acquisition of the brand name and trademark rights for Vysov & Vysov M (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market.

The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country.

Vildagliptin is an orally active, potent and selective DPP-4 inhibit or that improves glycemic control in patients primarily by enhancing pancreatic (α and β) is let functions.

Cipla says that the drug is backed by strong clinical data & is therefore a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus. The current market size of Vildagliptin is INR 818 Cr. as per IQVIA MAT Nov’ 2019 in India.

Nikhil Chopra, Executive Vice-President & Head India Business, Cipla Ltd said, “Owing to the increased affordability of Vildagliptinitis more accesible for better management of the disease. Cipla’s acquisition of the trademark rights of Vysov will enable us to contribute to easier Access of the drug in India.”

The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India.